2023 World Conference on Lung Cancer (Posters)-EP12.01. Association of CYP450 and Drug Efflux Transporters Polymorphism Influence Outcomes of Thai Non-small Cell Lung Cancer Treated with Osimertinib

EP12.01. Association of CYP450 and Drug Efflux Transporters Polymorphism Influence Outcomes of Thai Non-small Cell Lung Cancer Treated with Osimertinib - PDF(Slides)

Back to course

Pdf Summary

Teerapat Majam from the School of Pharmacy at Walailak University in Thailand conducted a study on the association between genetic variations and treatment outcomes of Thai patients with non-small-cell lung cancer (NSCLC) who were treated with Osimertinib. Osimertinib is metabolized by enzymes called cytochrome P450 (CYP450), and variations in these enzymes can affect drug metabolism. The study aimed to determine the association between specific genetic variations, known as single nucleotide polymorphisms (SNPs), and adverse drug reactions (ADRs) as well as treatment efficacy outcomes.<br /><br />The study included 63 NSCLC patients, with a median age of 68 years. The researchers genotyped 17 SNPs and analyzed their association with ADRs and treatment outcomes. They found that certain genetic variations increased the incidence of specific ADRs such as rash, diarrhea, myalgia, urticaria, paronychia, and alopecia. Additionally, some SNPs were associated with decreased progression-free survival and time to treatment failure.<br /><br />The study also compared the allele frequency of certain SNPs in different ethnic groups and found significant differences. This suggests that genetic variations may contribute to the differences in drug response and incidence of ADRs between patient populations.<br /><br />The findings of this study highlight the importance of considering genetic variations in CYP450 enzymes when prescribing Osimertinib for NSCLC patients. The results suggest that personalized medicine approaches that take into account individual genetic profiles may lead to improved treatment outcomes and reduced incidence of ADRs. Further research is needed to validate these findings and explore the potential impact of genetic differences on drug response in different populations.

Asset Subtitle

Teerapat Majam

Meta Tag

Speaker Teerapat Majam

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

genetic variations

treatment outcomes

NSCLC

Osimertinib

cytochrome P450

SNPs

adverse drug reactions

progression-free survival

allele frequency

personalized medicine